Novartis’ Afinitor Disperz wins new TSC-related approval

11th April 2018 Uncategorised 0

Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.

More: Novartis’ Afinitor Disperz wins new TSC-related approval
Source: News